Search

everythinglearnresearchcommunity

for

Search:↓

User shares 3-month progress with Big3 treatment (finasteride 0.15mg, minox twice a day, 0.75mm microneedling weekly). Others discuss results, dosage, and potential benefits of higher finasteride dose.

Many people experience hair loss but don't treat it. Common treatments include Minoxidil, Finasteride, and microneedling.

19-year-old experiencing hair loss seeks advice on treatments. Suggestions include Finasteride, Minoxidil, microneedling, hair systems, and consulting a dermatologist.

The user is using topical finasteride and is considering adding minoxidil despite concerns about dependency and side effects. Another user suggests that finasteride alone can reverse hair loss, but adding minoxidil and microneedling may improve results.

Minoxidil may cause facial aging or wrinkles, though opinions vary. Some users report side effects like dark circles and facial bloating, while others attribute changes to genetics or other factors.

A user who has had positive results from using a regimen of microneedling, finasteride, minoxidil, peppermint oil, keto shampoo and DHT organic shampoo for hair growth. The conversation also addressed whether to use .5mg or 1mg of finasteride and the difference between dermapens and rollers.

The user tried Finasteride, Dutasteride, Minoxidil, RU58841, dermarolling, and oral castor oil for hair loss. They found RU58841 and Minoxidil most effective with no side effects, while Finasteride and Dutasteride caused sexual side effects.

Exploring the effectiveness of redensyl, a hair loss treatment, compared to minoxidil and finasteride. People shared experiences using redensyl and products containing it, such as The Ordinary Hair Serum.

The post and conversation are about microneedling as a treatment for alopecia. It provides a comprehensive review of scientific literature on the technique and its application.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.

A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.

A 25-year-old is experiencing mild hair loss and is using a regimen including scalp brushing, dermarolling, topical minoxidil, caffeine, melatonin, and a DHT-blocking shampoo. Another person shares their struggle with hair loss due to drug use and plans to start finasteride while trying to quit drugs.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Significant hair regrowth was achieved using Minoxidil, Dutasteride, and derma stamping. The user noted improved hair quality and thickness with no side effects.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

Hair loss is a common issue, with treatments like finasteride and minoxidil used but not as permanent cures. Frustration exists over societal perceptions and the lack of a definitive solution.

Hair loss treatments, specifically finasteride and minoxidil, being used by wealthy individuals to combat their genetic predisposition to baldness. It also discussed other potential treatments such as RU58841 and dutasteride.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.